胸腺五肽辅助治疗菌阳肺结核的临床疗效及对免疫功能的影响

Effect of thymopetidum in the adjunctive therapy of sputum positive pulmonary tuberculosis and its influence on immune function

目的:观察胸腺五肽辅助治疗痰涂片镜检抗酸杆菌阳性(简称菌阳)肺结核的临床疗效及对机体免疫功能的影响。方法:选择160例菌阳肺结核患者,随机分为观察组和对照组各80例,对照组采用单纯化疗方案治疗,观察组在对照组的基础上联合胸腺五肽治疗,观察两组患者临床疗效及免疫功能改善情况。结果:治疗后观察组临床症状消失情况明显好于对照组(P>0.05),不良反应发生率明显低于对照组(P=0.036 4),痰菌转阴率在治疗后随访的各个时间段均明显高于对照组(P<0.05),治疗总有效率明显高于对照组(P=0.000 0);治疗后观察组CD3^+、CD4^+和CD4^+/CD8^+水平均明显高于治疗前和治疗后的对照组,而CD8^+水平均明显低于治疗前和治疗后的对照组(P<0.05);两组患者均未发生明显的不良反应。结论:胸腺五肽辅助治疗菌阳肺结核可显著增强患者免疫功能,改善患者临床症状与体征,提高临床治疗效果,值得临床推广使用。

Objective： To observe the clinical efficacy of thymopentin in the adjunctive therapy of positive pulmonary tuberculosis and the influence on immune function. Methods： 160 cases of acid-fast bacilli sputum smear microscopy-positive tuberculosis were selected as research subjects and were randomly divided into observation group and control group with each of 80 patients. The control group was simply treated with chemotherapy,while the observation group was combined with thymopentin for treatment on the basis of the control group. The clinical efficacy and the improvement of immune function were observed in both groups of patients.Results： After treatment,the disappearance of clinical symptoms in the observation group was significantly higher than in the control group（ P 〉 0. 05）,the rate of adverse reactions of patients in the observation group was significantly lower than in the control group（ P = 0. 036 4）,the sputum negative conversion rate of the patients in the observation group in the respective visit periods after treatment was were significantly higher than in the control group（ P 〈 0. 05）,and the total effective rate of the patients in the observation group after treatment was significantly higher than in the control group（ P = 0. 000 0）. The observation group after treatment was found that the levels of CD3~＋,CD4~＋ and CD4~＋/ CD8~＋ were significantly higher than the control group before and after treatment,while the level of CD8~＋ was significantly lower than the control group before and after treatment（ P 〈0. 05）,and no obvious adverse reaction was found in the two groups. Conclusion： Thymopentin in the adjunctive therapy of positive pulmonary tuberculosis can significantly enhance the immune function,improve the clinical symptoms and signs,and enhance the clinical outcomes of patients,which worth of clinical use.